Ionis Pharmaceuticals, Inc. Proceeds from Sale of Equity Method Investments
Ionis Pharmaceuticals, Inc. (IONS) reported Proceeds from Sale of Equity Method Investments of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2020-03-02
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for the quarter ending 2018-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for the quarter ending 2018-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for the quarter ending 2018-06-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for fiscal 2019 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for fiscal 2017 was $2.51M, a 43.88% decline from fiscal 2016.
- Ionis Pharmaceuticals, Inc. proceeds from sale of equity method investments for fiscal 2016 was $4.47M, a 82.50% decline from fiscal 2015.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $2.51M 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $2.51M 10-Q · filed 2018-11-06 | $6.97M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.51M 10-Q · filed 2018-08-07 | $6.97M derived: sum of 3 quarters · filed 2019-03-01 | $6.97M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $2.51M 10-Q · filed 2018-05-07 | $6.97M derived: sum of 2 quarters · filed 2019-03-01 | $6.97M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $4.47M derived: sum of 2 quarters · filed 2019-03-01 | $4.47M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $25.53M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |